• Biologie

  • Progression et métastases

  • Poumon

L1 Cell Adhesion Molecule Promotes Tumorigenicity and Metastatic Potential in Non-Small-Cell Lung Cancer

Menée in vitro et à l'aide de xénogreffes, cette étude met en évidence le rôle joué par une molécule d'adhérence cellulaire, L1CAM, dans le processus métastatique d'un cancer du poumon non à petites cellules

Purpose: Non-small-cell lung cancer (NSCLC) is a highly metastatic cancer with limited treatment options, thus requiring development of novel targeted therapies. Our group previously identified L1 cell adhesion molecule (L1CAM) expression as a member of a prognostic multi-gene expression signature for NSCLC patients. However, there is little information on the biological function of L1CAM in lung cancer cells. The present study investigates the functional and prognostic role of L1CAM in NSCLC. Experimental Design: Cox proportional hazards regression analysis was performed on four independent published mRNA expression datasets of primary NSCLCs. L1CAM expression was suppressed by short-hairpin RNA (shRNA)-mediated silencing in human NSCLC cell lines. Effects were assessed by examining in vitro migration and invasion, in vivo tumorigenicity in mice, and metastatic potential using an orthotopic xenograft rat model of lung cancer. Results: L1CAM is an independent prognostic marker in resected NSCLC patients, with overexpression being associated strongly with worse prognosis. L1CAM downregulation significantly decreased cell motility and invasiveness in lung cancer cells and reduced tumor formation and growth in mice. Cells with L1CAM downregulation were deficient in constitutive extracellular-signal regulated kinase (Erk) activation. Orthotopic studies showed that L1CAM suppression in highly metastatic lung cancer cells significantly decreases spread to distant organs, including bone and kidney. Conclusion: L1CAM is a novel pro-metastatic gene in NSCLC and its downregulation may effectively suppress NSCLC tumor growth and metastasis. Targeted inhibition of L1CAM may be a novel therapy for NSCLC.

Clinical Cancer Research 2012

Voir le bulletin